Oxygenta Pharmaceutical MD, chairman, board of directors and AGM
BSE: 524636Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹47.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹170 Cr2,423rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 27 Jul 2026
- −15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,726
Oxygenta Pharmaceutical board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Company Secretary and Compliance OfficerKumkum Bajaj
8 directors4 independent3 executive1 non-executive
- Chandra Mouliswar Reddy GangavaramExecutive · joined Jun 2025 · 1 listed board · 1 committee seat
- Balasubba Reddy MamillaExecutive · joined Jun 2025 · 1 listed board · 3 committee seats
- Vedavathi GangavaramNon-executive · joined Jun 2025 · 1 listed board · 1 committee seat, 1 as chair
- Sidda Reddy KanuparthiIndependent · joined Jun 2025 · 12 months as independent · 1 listed board · 1 as independent · 3 committee seats, 1 as chair
- Veera Reddy AravaIndependent · joined Jun 2025 · 12 months as independent · 1 listed board · 1 as independent · 4 committee seats, 1 as chair
- Sharvari Swapnil ShindeIndependent · joined Jun 2025 · 12 months as independent · 1 listed board · 1 as independent · 2 committee seats
- Amireddy Venkatesu ReddyExecutive · joined May 2026 · 1 listed board
- Janardhana Reddy YeddulaIndependent · joined May 2026 · 1 month as independent · 2 listed boards · 2 as independent · 2 committee seats, 2 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
9 directors who left
- Dr. Sai Sudhakar Vankineni, left 18 Aug 2025: Others
- Sanagari Kondal Reddy, left 18 Aug 2025: Others
- Padmaja Surapureddy, left 20 Jun 2025: Others
- Bharath Reddy Guntuku, left 20 Jun 2025: Others
- Raghavender Rao Kanuganti, left 20 Jun 2025: Others
- Sunil Vishram Chawda, left 20 Jun 2025: Others
- Sravani Reddy Gantla, left 20 Jun 2025: Others
- Aakanksha Sachin Dubey, left 20 Jun 2025: Others
- VIDYASAGAR DEVABHAKTHUNI, left 1 Oct 2024: Tenure Completion
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 23 May 20266 of 6 present3 independent · 107 days in between
- 4 Feb 20266 of 6 present3 independent
Audit Committee
Chair Sidda Reddy Kanuparthi
Sharvari Swapnil Shinde, Veera Reddy Arava, Chandra Mouliswar Reddy Gangavaram
- 23 May 20264 of 4 present3 independent · 107 days in between
- 4 Feb 20264 of 4 present3 independent
Nomination and remuneration committee
Chair Veera Reddy Arava
Sidda Reddy Kanuparthi, Sharvari Swapnil Shinde
- 23 May 20263 of 3 present3 independent · 107 days in between
- 4 Feb 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair Veera Reddy Arava
Sidda Reddy Kanuparthi, Sharvari Swapnil Shinde, Balasubba Reddy Mamilla
- 4 Feb 20264 of 4 present3 independent
Independent Directors Meeting
- 4 Feb 20263 of 3 present3 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/s. A.M. Reddy & D.R. ReddyPeer-review certificate valid to Feb 2027
1 earlier auditor
- A M Reddy & D R ReddyNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Oxygenta Pharmaceutical AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Oxygenta Pharmaceutical share news and announcements
Annual general meeting, 21 Aug 2026
10,308 shareholders on the register on 14 Aug 2026; present: 2 promoters and 73 others; votes counted by Aakanksha Sachin Dubey / Aakankha Dubey & Co..The company's voting result (opens in a new tab)
To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended 31st March 2026, together with the Reports of the Board of Directors and Auditor's thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 12.09% · promoters 0.00% · institutions 0.00% · other public 27.84%
- To appoint a director in place of Mr. Balasubba Reddy Mamilla (DIN: 01998852), who retires by rotation and being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 12.09% · promoters 0.00% · institutions 0.00% · other public 27.84%
- To appoint Mr. Amireddy Venkatesu Reddy (DIN: 11087687) as a Director and Whole-time Director of the Company.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 12.09% · promoters 0.00% · institutions 0.00% · other public 27.84%
- To appoint Mr. Janardhana Reddy Yeddula (DIN 03207357) as an Independent Director of the Company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 12.09% · promoters 0.00% · institutions 0.00% · other public 27.84%
- To approve Material Related Party transactions (Sale and Purchase) of the company with M/s. Virupaksha Organics Limited, Holding CompanyOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 12.09% · promoters 0.00% · institutions 0.00% · other public 27.84%
- To approve Material Related Party transactions (Loan and Guarantee) of the Company with M/s. Virupaksha Organics Limited, Holding CompanyOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 12.09% · promoters 0.00% · institutions 0.00% · other public 27.84%
- Ratification of payment of Remuneration to the Cost Auditor for the Financial Year 2026-27.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 12.09% · promoters 0.00% · institutions 0.00% · other public 27.84%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- No
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.